GlassScriptPhysician profile
Michael B Andrews
NPI 1245234608
$5,131.64
in general payments reported to CMS, 2019-2025
45 companies · $877 in 2025
The $877 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,485 · 2020: $478 · 2021: $503 · 2022: $267 · 2023: $534 · 2024: $989 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,111 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,111.40 |
| Education | $287.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $675.09 | 2019-2025 | |
| Seagen INC. | $593.00 | 2019-2023 | Tukysa, Adcetris, Padcev |
| E.R. Squibb & Sons, L.L.C. | $429.23 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $288.96 | 2019-2025 | Imbruvica, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $269.76 | 2019-2023 | Keytruda |
| Novartis Pharmaceuticals Corporation | $251.08 | 2019-2025 | |
| Abbvie INC. | $248.82 | 2019-2025 | |
| Celgene Corporation | $228.13 | 2019-2025 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $225.17 | 2019-2025 | Tagrisso, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $191.30 | 2019-2025 | Fruzaqla, Iclusig |
| Ipsen Biopharmaceuticals, INC | $158.14 | 2019-2020 | |
| Daiichi Sankyo INC. | $156.80 | 2022-2025 | Enhertu, Datroway |
| Pharmacyclics LLC, An Abbvie Company | $150.84 | 2019-2023 | Imbruvica |
| Astellas Pharma US INC | $128.75 | 2019-2024 | |
| Genentech USA, INC. | $110.34 | 2019-2023 | Gazyva, Lunsumio, Polivy |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.